AKRO - Akero Therapeutics (AKRO) Reports Biopsy Data and Safety/Tolerability for 16-Week Phase 2a Study in NASH Patients - Slideshow
The following slide deck was published by Akero Therapeutics, Inc. in conjunction with this
Link your Twitter Account to Market Wire News
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
home / news releases / AKRO - Akero Therapeutics (AKRO) Reports Biopsy Data and Safety/Tolerability for 16-Week Phase 2a Study in NASH Patients - Slideshow
Stock Information
Get AKRO Alerts
News, Short Squeeze, Breakout and More Instantly...